Elite PharmaceuticalsELTP +4.08%42 Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates ELTP with a GF Score™ of 42/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 504 Drug Manufacturers companies, Elite Pharmaceuticals ranks worse than 198412.5% on this metric.
As of today (2026-06-26), the Forward Annual Dividend Yield of Elite Pharmaceuticals is 0.00%.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Elite Pharmaceuticals is 0.00%.
ELTP's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.095 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Elite Pharmaceuticals Forward Dividend Yield % Related Terms
ELTP vs SIGA, ORGO, EOLS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Elite Pharmaceuticals (ELTP) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Elite Pharmaceuticals and its competitors. According to the industry distribution chart, Elite Pharmaceuticals ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Elite Pharmaceuticals' Forward Dividend Yield % too high?
Elite Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Elite Pharmaceuticals ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Forward Dividend Yield % compare to SIGA and ORGO?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Elite Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 2.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.39 — trading 32.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Elite Pharmaceuticals' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.39 is trading 32.5% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Forward Dividend Yield %: 0.00%
GF Value™: $0.57 vs. price of $0.39 (32.5% below fair value)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
42GF Score
Get the complete analysis for ELTP
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 